Lakewood-Amedex Biotherapeutics Inc. (LABT) company profile
Close on Nov 13, 2026Market cap $669.20KP/E –Yield –
About Lakewood-Amedex Biotherapeutics
Pharmaceutical Preparations, SIC 2834
Lakewood-Amedex Biotherapeutics Inc. is listed on Nasdaq under the ticker LABT, in the SEC industry Pharmaceutical Preparations. It is incorporated in Nevada and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Lakewood-Amedex Biotherapeutics Inc.
- Headquarters
- University Park, FL
- Address
- 8031 Cooper Creek Blvd., Suite 103 34201
- Phone
- (941) 225-2515
- Website
- lakewoodamedex.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- LABT
- Exchange
- Nasdaq
- IPO date
- Apr 23, 2026
- Shares outstanding
- 2M, Aug 3, 2026
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Jun 22, 2026
- SEC CIK
- 2079272
- CUSIP
- 51255A201
- ISIN
- US51255A2015
- FIGI
- BBG01ZK61BH1
- Share class FIGI
- BBG01ZK61CF1
- EIN
- 20-5274304
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kelvin Cooper | Chief Executive Officer, Director | 300,594 |
| Thomas Balzer | Chief Medical Officer | 255,322 |
| Peter Ceccacci | Chief Financial Officer | 468,148 |
| Joseph Edward Tucker | Director | 0 |
| Leonard James DeRoma | Director | 187,736 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Total | vs. prior year |
|---|---|---|---|---|
| Kelvin Cooper CEO | $190.42K | $372.96K | $563.38K | -20% |
| Peter Ceccacci CFO | $160.00K | $372.96K | $532.96K | +21% |
| Thomas Balzer CMO | $177.92K | $310.80K | $488.72K | -26% |
| Peter B. Corr Executive Chair | $48.00K | – | $48.00K | 0% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 23, 2026
- Securities offered
- 4,689,177
- Exchange
- Nasdaq
- First trading day
- Apr 23, 2026
- First-day close
- $8.65
- Lock-up ends (est.)
- Oct 20, 2026
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 23, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 17, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?